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A simple flow-injection analysis procedure was developed for determining captopril in pharmaceutical 
formulations employing a novel solid-phase reactor containing silver thiocyanate immobilized in a 
castor oil derivative polyurethane resin. The method was based on silver mercaptide formation between 
the captopril and Ag(I) in the solid-phase reactor. During such a reaction, the SCN– anion was released 
and reacted with Fe3+, which generated the FeSCN2+ complex that was continuously monitored at 
480 nm. The analytical curve was linear in the captopril concentration range from 3.0 × 10−4 mol L−1 to 
1.1 × 10−3 mol L−1 with a detection limit of 8.0 × 10−5 mol L−1. Recoveries between 97.5% and 103% and 
a relative standard deviation of 2% for a solution containing 6.0 × 10−4 mol L−1 captopril (n = 12) were 
obtained. The sample throughput was 40 h–1 and the results obtained for captopril in pharmaceutical 
formulations using this procedure and those obtained using a pharmacopoeia procedure were in agreement 
at a 95% conﬁdence level.
Uniterms: AgSCN. Captopril/determination. Flow-injection. Polyurethane resin. Solid-phase reactor.
Um procedimento simples de análise por injeção em fluxo foi desenvolvido para a determinação de 
captopril em formulações farmacêuticas empregando um novo reator em fase sólida contendo tiocianato 
de prata imobilizado em resina poliuretana obtida a partir de óleo de mamona. O método foi baseado 
na formação de um mercapto composto de prata, no reator em fase sólida, obtido entre o captopril 
e Ag (I) imobilizada. Durante a reação, íons SCN− eram liberados e reagiam com Fe3+, gerando o 
complexo FeSCN2+, que foi continuamente monitorado em 480 nm. A curva analítica foi linear no 
intervalo de concentração de captopril entre 3,0 × 10−4 a 1,1 × 10−3 mol L−1 com um limite de detecção 
de 8,0 × 10−5 mol L−1. Recuperações entre 97,5–103% e desvio padrão relativo de 2% para uma solução 
contendo 6,0 × 10−4 mol L−1 de captopril (n = 12) foram obtidos. A frequência de amostragem foi de 
40 h–1 e os resultados obtidos para captopril em formulações farmacêuticas utilizando este procedimento 
e o da Farmacopeia, estão de acordo em um nível de conﬁança de 95%.
Unitermos: AgSCN. Captopril/determinação. Injeção em fluxo. Resina poliuretana. Reator em fase sólida.
INTRODUCTION
Captopril,1-[(2S)-3-mercapto-2-methyl propionyl]-
l-proline (Figure 1) is an angiotensin converting enzyme 
(ACE) inhibitor, which reduces peripheral resistance and 
lowers blood pressure (Rubin et al., 1978). This compound 
can also be used to treat congestive heart failure (Goodman, 
Gilman, 1996). Captopril contains a sulphydryl group 
and forms disulphides and endogeneous thiol-containing 
compounds (cysteine, glutathione), as well as disulphide 
dimmer of the parent compound (Vancea et al., 2009).
Since it is widely used in high blood pressure con-
trol all over the world, numerous analytical methods have 
been developed for the quantitative determination of this 
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FIGURE 1 – Molecular structure of captopril.
analyte in pharmaceutical formulations. Methods based on 
titrimetric (Mohamed et al., 1983; Basavaiah, Prameela, 
2004; Schmidt et al., 2009), spectrophotometric (Suarez 
et al., 2007; Suarez et al., 2009; Suarez et al., 2011), 
fluorimetric (Al-Ghannam et al., 2002; Chen, Cai, 2003), 
amperometric (Marcolino-Junior et al., 2009), conducto-
metric (Lourenção et al., 2008), voltammetric (Ziyatdi-
nova et al., 2006; Rezaei, Damiri, 2008; Karimi-Maleh et 
al., 2010), and chemiluminescence (Pulgarín et al., 2005) 
procedures have been previously described. The Brazilian 
Pharmacopeia recommends an iodimetric method for the 
determination of captopril in pharmaceutical formulations 
(Farmacopéia Brasileira, 1977).
The use of solid-phase reactors incorporated in flow-
injection manifolds is a well-established methodology 
(Kojlo, Martínez-Calatayud, 1995). The reactor is generally 
constructed by incorporating oxidizing/reducing agents, 
insoluble salts, or ion exchange resins into a small column. 
The immobilization procedure is fairly expeditious, simple, 
and nonspeciﬁc (Pereira, Fatibello-Filho, 1998).
Solid-phase reactors are based on the immobiliza-
tion of the reagents at a predeﬁned point of the manifold. 
The sample zone is driven by the carrier stream through 
the reactor and conversion of the analyte takes place at 
the solid-solution interface (Tzanavaras, Themelis, 2007).
Some advantages of the use of solid-phase reactors 
in flow systems include lower consumption of reagents, 
greater stability, reproducible long-life supplies, and 
greater sensitivity and throughput.
Several procedures, utilizing solid-phase reactors 
that are based on the immobilization of insoluble salts 
such as Zn3(PO4)2 (Suarez et al., 2007), Ag2C6Cl2O4 (Su-
arez et al. 2009), Fe(OH)3 (Pereira, Fatibello-Filho, 1998), 
CoCO3 (Icardo et al., 1998; Corominas et al., 2005), AgCl 
(Marcolino-Junior et al., 2005), and PbO2 (Teixeira et al., 
2002) in a polymeric matrix have been described in the 
literature. A typical immobilization procedure involves 
mixing the salt with polyester resin followed by the addi-
tion of a catalyst (methylethyl ketone).
Polyurethanes (PU) are versatile polymers that can 
be prepared as thermoplastic, thermosetting, elastomeric, 
foam, or adhesive by an appropriate choice of precur-
sors. The remarkable properties of polyurethane include 
adhesion, abrasion electric resistance, hardness, chemical 
resistance to organic solvents, stability at low tempera-
ture, and tolerance to high humidity, as well as the ease 
of application, catalysis, and preparation of composite 
materials (Mendes et al., 2002). Another feature of the 
growing market demand is the use of polyols derived from 
vegetable oils (e.g. castor oil), a renewable source, and the 
simplicity of synthesis of derivatives, such as that used in 
the present study (Azevedo et al., 2009).
This study describes a new solid-phase reactor 
ﬁlled with an active phase consisting of silver thiocyanate 
dispersed in a castor oil polyurethane resin. The main 
advantages of such materials are their high resistance 
to organic solvents and the oily nature of the resin that 
provides a hydrophobic character to the ﬁnal polymer, 
preventing a swelling effect from epoxy resins observed in 
other solid-phase reactors, when such materials are used in 
the aqueous media. Another interesting feature is that the 
polymer is composed from a bicomponent liquid system, 
the polyol (adhesive), and the prepolymer (hardener); the 
solid-phase is prepared by simply mixing the noncured 
precursors with the active reagent and the mixture is left 
to cure. The new reactor has been used in the determina-
tion of the antihypertensive captopril in pharmaceutical 
formulations, demonstrating its usefulness.
EXPERIMENTAL
Apparatus
The flow-injection system assembly is depicted in 
Figure 2. A peristaltic pump (Ismatec, model 7618-50, 
8-channel, Zurich, Switzerland) supplied with Tygon® 
pump tubing was used for the propulsion of the solutions.
Sample and reference solutions were inserted into 
the flow system by a three-piece homemade manual 
injector-commutator made from Perspex containing two 
ﬁxed bars and a sliding central bar (Krug et al., 1986).
Flow-injection spectrophotometric measurements 
were carried out using a Genesis 20 (Thermospectronics, 
USA) spectrophotometer, model 435, equipped with a 
homemade glass flow-cell (optical path, 1.0cm).
The molecular absorption spectra were obtained in 
a linear diode array Multispec 1501 spectrophotometer 
(Shimadzu, Japan), using a quartz cuvette with an optical 
path of 1.00 cm and volume of 4 mL.
Reagents and solutions
All solutions were prepared using water from an 
EasyPure RoDi purifying system (Barnstead, Thermo 
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Scientiﬁc). All chemicals were analytical-reagent grade 
and were used without further puriﬁcation.
The 5.0 × 10−3 mol L−1 captopril stock solution 
was prepared by dissolving 108.6 mg of this compound 
(Aldrich) in 1.0 × 10−2 mol L–1 HNO3 solution and com-
pleted in a 100.0 mL calibrated flask with the same acid 
solution. The reference solutions within the range of 
3.0 × 10−4 mol L−1 to 1.1 × 10−3 mol L−1 were obtained by 
appropriate dilution of this stock solution with the same 
nitric acid solution in a 25.0 mL calibrated flask.
A 1.0 × 10−2 mol L−1 Fe(NO3)3.9H2O (Aldrich) 
solution was prepared by dissolving 404 mg in a 
1.0 × 10−2 mol L−1 nitric acid solution, and the volume was 
made up to 100 mL in a calibrated flask using the same acid 
solution in order to prevent hydrolysis of the Fe(III) ion.
Preparation and analysis of the pharmaceutical 
samples
For analysis, Brazilian commercial tablets of capto-
pril, containing 12.5 and 25.0 mg, according to the label, 
were used. Thus, 10 tablets of each formulation of the drug 
were weighed and powdered in a mortar. The resulting 
powder was diluted in deionized water and ﬁltrated. Suit-
able dilutions were made to obtain a ﬁnal concentration 
of captopril within the linear range of the analytical and 
analyzed curve using the developed flow procedure. The 
obtained results were compared with the standard iodime-
tric procedure (Farmacopéia Brasileira, 1977).
Preparation and immobilization of AgSCN
For the preparation of the solid-phase reactor, 1.5 g 
AgSCN was mixed with 0.7 g of polyurethane resin and 
FIGURE 2 – Schematic diagram of the flow-injection system for spectrophotometric determination of captopril at 25 °C: C, Milli-Q 
water carrier (1.1 mL min−1 ); I, scheme of the sliding-bar manual commutator; PP, peristaltic pump; L, sample loop (500 µL); S, 
sample or reference solutions; SPR, solid-phase reactor (100 mm × 2.0 mm i.d.) containing silver thiocyanate immobilized in a 
polyurethane resin; R, 1.0 × 10−2 mol L−1 Fe3+ in 1.0 × 10−2 mol L−1 HNO3 (1.1 mL min−1); X, acrylic confluence; B, reactor coil (50 
cm × 0.8 mm i.d.); D, spectrophotometer at 480 nm; and W, waste.
homogenized by manual mixing until an increase in the 
viscosity of the mixture was observed, and then kept at 
room temperature for 24 h. After this, it was ground in a 
Willy-type mill (Marconi, MA 048).
The particle size was selected by passing the pulver-
ized material through stainless steel sieves (Bertel, Brazil) 
with different mesh sizes (35, 48, 60 and 100 mesh). The 
solid-phase reactor was constructed by packing particles 
of 60–100 mesh, which were inserted with the aid of a sy-
ringe, in PTFE tubing (100 mm long × 2.0 mm i.d). Pieces 
of glass wool were placed at both the ends of the tube to 
prevent fragment displacement through the transmission 
lines. The solid-phase reactor was inserted between the 
injector-commutator and the detector as shown in Figure 2.
RESULTS AND DISCUSSION
The principle of the determination of captopril em-
ploying a solid-phase reactor containing silver thiocyanate 
(AgSCN) is based on the following precipitation (1) and 
complex (2) reactions:
R-SH(aq) + AgSCN(s)  R-SAg(s) + SCN− (aq) + H+(aq)  (Eq. 1)
Fe3+(aq) + SCN−(aq)  FeSCN2+(aq)   (Eq. 2)
The reaction between silver thiocyanate and cap-
topril leads to the displacement of thiocyanate and the 
formation of the well-known red complex with Fe(III) 
(Vogel, 1979; Baccan, 2001), which can be detected 
spectrophotometrically. When an aqueous captopril solu-
tion flowed through the solid-phase reactor packed with 
AgSCN entrapped in the polyurethane resin, SCN− ions 
were released from the reactor. The studies of chemical 
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and hydrodynamic parameters were carried out using the 
flow-injection system depicted in Figure 2.
The univariated method was employed in all studies 
and was performed to identify a better balance between the 
magnitude and precision of analytical signals, the stability 
of baseline, and the sample throughput. The best condi-
tions for the precipitation reaction between captopril and 
Ag (I) and the complex reaction between the anion thio-
cyanate displaced by the reactor and Fe (III) were studied.
Initially, the most appropriate carriers’ solutions 
were tested, since the lifespan of the solid-phase reactor 
is directly related to the solution flowing through it. The 
acetate buffer was not studied once it forms a complex 
with Fe(III). In the same way, phosphate buffer was not 
used to prevent possible precipitation of FePO4(s). Sulfuric, 
hydrochloric, and phosphoric acids, as well as sodium and 
potassium hydroxides, were not tested since these acids 
and bases form insoluble salts with silver ions.
Thus, nitric acid solutions were studied as carriers. 
During this study, it was noted that the absorbance signals 
obtained using a 5.0 × 10−3 mol L−1 HNO3 solution were 
20% lower than when using water. This decrease in the 
analytical signal is probably due to the difﬁculty in re-
moving the acidic hydrogen from the captopril molecule 
(R-SH), because once in acidic medium, the displacement 
of the reaction toward the reactants occurs, as can be seen 
from the reaction represented in Eq. 1. Thus, water was 
employed in further experiments.
Reaction conditions and flow-injection 
parameters
The response of the flow-injection system was 
studied by varying the inner diameter and length of the 
reactor, the mass/mass ratios (AgSCN/polyurethane), and 
the particle sizes.
The internal diameter of the reactor was evaluated 
for 1.0, 1.5, 2.0, and 3.0 mm. The reactors with 1.0 and 
1.5 mm were very difﬁcult to pack. The reactor with 3.0 
mm caused a pronounced dispersion of the sample zone. 
The reactor with 2.0 mm produced good sensitivity and 
adequate stability of the baseline and, consequently, was 
chosen for further experiments.
The influence of the solid-phase reactor length 
was evaluated from 3.0 to 12 cm. According to Figure 3, 
the absorbance signals increased with increments in the 
reactor length, but an undesirable increase of the hydro-
dynamic pressure was observed for reactors longer than 
10.0 cm. So, a 10.0 cm reactor length was selected for 
further experiments.
The mass/mass ratios (AgSCN/polyurethane) of 
1:2, 1:1, and 2:1 (m/m) were evaluated. The sensitivity 
(slope of the analytical curve) increased with the mass of 
AgSCN incorporated in the polyurethane resin, as shown 
in Figure 4. Thus, a 2:1 ratio was selected, taking into ac-
count the magnitude of the analytical signal.
The effect of particle size was studied in three size 
ranges (35–48, 48–60 and 60–100 mesh), selected by 
passing the particles through mesh sieves of known sizes. 
The 60–100 mesh particle size presented the highest ab-
sorbance signal and was selected for this reason.
Flow-injection parameters
The influence of Fe(III) concentration on the analyti-
FIGURE 3 – Influence of reactor length (cm) on the analytical 
signal.
FIGURE 4 – Influence of reactor composition, AgSCN (m/m), 
on the analytical signal.
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FIGURE 5 – Influence of Fe(III) concentration on the analytical 
signal.
cal signal was evaluated in the range from 3.0 × 10−3 to 
5.0 × 10−2 mol L−1 for a 1.0 × 10−3 mol L−1 reference capto-
pril solution. As can be seen in Figure 5, it was observed 
that the height of the peaks increased with the increase in 
Fe(III) concentration up to 1.0 × 10−2 mol L−1 and remained 
practically constant for higher concentrations of this re-
agent. Therefore, a 1.0 × 10−2 mol L−1 Fe(III) solution was 
chosen for further experiments.
Figure 6 shows the effect of the volumes of captopril 
inserted in the flow system by varying the volumes of the 
loop (L) between 100 and 700 mL, keeping the concen-
tration of captopril at 1.0 × 10−3 mol L−1. The analytical 
signal increased from 100 to 500 μL for captopril, remain-
ing almost constant at higher volumes. Consequently, the 
FIGURE 6 – Influence of sample volume on the analytical signal.
volume of 500 μL was chosen for the sample, based on 
the most effective balance of repeatability and magnitude 
of the analytical signal.
The influence of the reactor coil length (B) is shown 
in Figure 2, was also evaluated. The analytical signal 
was investigated in the 30–100 cm range. The analytical 
signal increased up to 50 cm, while higher lengths led 
to a decrease in the analytical signal because of sample 
dispersion. Consequently, a length of 50 cm for reactor 
coil B was selected.
The effect of the total flow rate was investigated in 
the range of 0.6–4.4 mL min−1. Best results were obtained 
with a flow rate of 1.1 mL min−1. For higher flow rates, the 
sensitivity decreased due to the short contact time between 
the sample zone and the silver thiocyanate particles in 
the solid-phase reactor. A flow rate of 1.1 mL min−1 was 
then selected taking into account the magnitude of the 
analytical signal, stability of the baseline, and low reagent 
consumption.
Table I presents the optimization of the chemical and 
flow-injection parameters studied in this work.
Analytical characteristics
Recoveries between 97.5% and 103% of captopril 
from ﬁve pharmaceutical formulations (n = 3) were ob-
tained by using the flow-injection procedure. In this study, 
2.0 × 10−1, 4.0 × 10−1 and 6.0 × 10−1 mmol L−1 of captopril 
were added to each product. The recovery results obtained 
suggest an absence of the matrix effect in the determina-
tion of captopril in those samples. Under optimum ex-
perimental conditions, the flow-injection system showed a 
linear response to captopril in the concentration range from 
3.0 × 10−4 to 1.1 × 10−3 mol L−1 (A= 0.0714 + 281.25 C; 
TABLE I – Study of chemical and flow-injection parameters
Parameter Evaluated range
Selected 
Value
Reactor composition AgSCN (m/m) 33%–66% 66%
Particle size (Mesh) 35–100 60–100
Reactor length (cm) 3.0–12 10
Reactor diameter (mm) 1.0–3.0 2.0
Carrier flow rate (mL min−1) 0.6–4.4 1.1
Fe3+ flow rate (mL min−1) 0.6–4.4 1.1
[Fe3+] (10−3 mol L−1) 3.0–50 10
Sample volume (µL) 100–700 500
Reactor coil length (cm) 30–100 50
F. C. Vicentini, W. T. Suarez, E. T. G. Cavalheiro, O. Fatibello-Filho330
r = 0.998, where A is the absorbance and C the concentra-
tion of captopril in mol L−1). The observed quantiﬁcation 
limit (tenfold blank standard deviation/slope) was 1.0 
× 10−4 mol L−1 and the detection limit (threefold blank 
standard deviation/slope) was 8.0 × 10−5 mol L−1. Typi-
cal transient signals corresponding to a linear calibration 
graph for captopril are shown in Figure 7.
The precision of the flow system was evaluated in 
two concentration levels (6.0 × 10−4 and 1.0 × 10-3 mol L-1). 
The relative standard deviations (RSDs) obtained were 
lower than 2% (n = 12) for both solutions and a sample 
throughput of 40 h–1 was attained. The transient signals 
are shown in Figure 8.
To examine the efﬁciency of the solid-phase reactor 
containing immobilized AgSCN in the polyurethane resin, 
experiments were performed with consecutive injections 
of captopril solutions. The reactors that were prepared pre-
sented high stability for at least eight hours under intense 
use in flowing solutions, when submitted to the consecu-
tive injection of 3.0 × 10−4 to 1.1 × 10−3 mol L−1 captopril. 
After this period, a decrease in the order of 20% on the 
slope of the analytical curve was observed.
Determination of captopril in pharmaceutical 
formulations
The proposed flow-injection system was applied 
for the determination of captopril in pharmaceutical 
formulations. The results obtained by the proposed flow 
method and those obtained by the comparative method 
(Bittencount, 1977) are in agreement within a 95% conﬁ-
dence level (t-paired test), conﬁrming the accuracy of the 
proposed flow-injection system employing a solid-phase 
reactor containing AgSCN immobilized in the polyure-
TABLE II – Determination of captopril in pharmaceutical formulations using the comparative method and the proposed flow-
injection method
Samples
Captopril Relative Error/%
Labeled Comparative Method Flow Method Er1 Er2
A 12.5* 12.7 ± 0.3 12.8 ± 0.1 2.4 0.8
B 25.0* 26.1 ± 0.2 25.8 ± 0.1 3.2 −1.1
C 25.0* 25.3 ± 0.2 26.2 ± 0.2 4.8 3.5
D 12.5* 12.8 ± 0.1 13.0 ± 0.4 4.0 1.6
E 25.0* 26.3 ± 0.3 25.5 ± 0.2 2.0 −3.0
* mg/tablet
n = 3, mean ± standard deviation, conﬁdence level 95%.
Er1 = relative error flow procedure vs. labeled value and Er2 = relative error flow procedure vs. comparative method.
FIGURE 7 – Typical transient signals in triplicate for reference 
captopril solutions ((A) 3.0 × 10−4; (B) 5.0 × 10−4; (C) 7.0 × 10−4; 
(D) 9.0 × 10−4; and (E) 1.1 × 10−3 mol L−1).
FIGURE 8 – Typical transient signals for reference solutions of 
captopril containing (A) 6.0 × 10−4 and (B) 1.0 × 10−3 mol L−1.
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TABLE III – Comparison of analytical characteristics of flow procedures for captopril determination
Reference *LOD (µmol L–1)
Linear range 
(µmol L–1)
Sample throughput
(h–1)
Coefﬁcient of variation 
(%)
Albero et al. (1993) 2.2 20–600 90 0.6
Tzanavaras et al. (2002) 12 <1200 60 0.8
Song et al. (2006) 0.01 0.032–4.6 120 3.0
Suarez et al. (2007) 5.0 10–800 60 0.20
Marcolino-Junior et al. (2009) 14 50–10000 42 3.7
Schmidt Jr. et al. (2009) 1.0 5–200 72 1.2
Suarez et al. (2009) 8.0 10–500 70 0.35
Schmidt Jr. et al. (2011) 3.0 10–400 60 0.5
Suarez et al. (2011) 30 50–400 70 0.20
Proposed system 80 300–1100 40 2.0
*LOD = Limit of Detection
thane resin. The results of the analysis are given in Table II.
Table III shows the analytical characteristics ob-
tained in this study and in other analytical systems de-
veloped for the determination of captopril. The primary 
advantage of the proposed flow-injection system is the 
lower generation of waste.
CONCLUSIONS
This study demonstrates the possibility of analyzing 
captopril in pharmaceutical products using a flow-injection 
system with spectrophotometric detection and could be 
extended to determine other drugs since it generates a pre-
cipitate with silver ions. The proposed method is simple, 
quick, and could be carried out with good precision and 
accuracy. The new solid-phase reactor containing AgSCN 
immobilized in the developed polyurethane resin derived 
from vegetable oil is easy to make and has a long lifetime 
of 500 reproducible results. As the polyurethane resin 
used here is an inert material with mechanical resistance 
it proved to be an interesting material for the preparation 
of solid reactors containing modiﬁers.
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